Literature DB >> 21199732

Impairment in immunomodulatory function of mesenchymal stem cells from multiple myeloma patients.

Bingzong Li1, Jinxing Fu, Ping Chen, Wenzhuo Zhuang.   

Abstract

BACKGROUND AND AIMS: Abnormality of immune regulation exists in multiple myeloma (MM). Mesenchymal stem cells (MSCs), a key regulator for immunomodulatory function, have decreased osteogenic potential in MM patients. Here we investigated the immunomodulatory function of MSCs from MM patients (MM-MSCs) and its relationship with decreased osteogenic potential.
METHODS: Real-time PCR was performed to detect the cytokines expressed in MM-MSCs (n = 22) and MSCs from normal donors (ND-MSCs, n = 11). Lymphocyte proliferative assay was used to detect the effect of MSCs on T cell proliferation. The effect of MSCs on T-cell cycle and T-cell activation markers expression were analyzed by flow cytometry. Flow cytometry and Western blot were used to detect apoptosis of T cells. Influence of T cells on osteogenic potential of MSCs was detected.
RESULTS: MM-MSCs exhibited increased expression of TGF-β1, IL-6, IL-3, TNF-α and RANKL and decreased expression of TGF-β2, TGF-β3 and FasL. The inhibitory effect of MM-MSCs on T.cell proliferative ability was attenuated. ND-MSCs silence more T cells in G0/G1 phase than MM-MSCs. The apoptosis-promoting effect of MM-MSCs on T cells seemed to be dampened. Expression of T-cell activation markers was significantly inhibited by ND-MSCs. T cells from normal donors possessed the ability to promote osteoblastic differentiation of ND-MSCs, but this ability of T cells both directly from MM patients and co-cultured with MM-MSCs was impaired.
CONCLUSIONS: MSCs from MM patients showed impaired immunoinhibitory capability on T cells, which in turn lose the ability to stimulate osteogenesis of MSCs. Copyright Â
© 2010 IMSS. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21199732     DOI: 10.1016/j.arcmed.2010.11.008

Source DB:  PubMed          Journal:  Arch Med Res        ISSN: 0188-4409            Impact factor:   2.235


  17 in total

Review 1.  Multiple myeloma mesenchymal stem cells: characterization, origin, and tumor-promoting effects.

Authors:  Michaela R Reagan; Irene M Ghobrial
Journal:  Clin Cancer Res       Date:  2011-11-07       Impact factor: 12.531

Review 2.  An overview of the role of cancer stem cells in spine tumors with a special focus on chordoma.

Authors:  Mojdeh Safari; Alireza Khoshnevisan
Journal:  World J Stem Cells       Date:  2014-01-26       Impact factor: 5.326

Review 3.  Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics.

Authors:  Antonio Garcia-Gomez; Fermin Sanchez-Guijo; M Consuelo Del Cañizo; Jesus F San Miguel; Mercedes Garayoa
Journal:  World J Stem Cells       Date:  2014-07-26       Impact factor: 5.326

4.  Activation of LTBP3 gene by a long noncoding RNA (lncRNA) MALAT1 transcript in mesenchymal stem cells from multiple myeloma.

Authors:  Bingzong Li; Ping Chen; Jing Qu; Lei Shi; Wenyue Zhuang; Jinxiang Fu; Jun Li; Xiaohui Zhang; Yu Sun; Wenzhuo Zhuang
Journal:  J Biol Chem       Date:  2014-09-03       Impact factor: 5.157

Review 5.  Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities.

Authors:  G Shay; L Hazlehurst; C C Lynch
Journal:  J Mol Med (Berl)       Date:  2015-10-01       Impact factor: 4.599

Review 6.  Mesenchymal stem cell secretome and regenerative therapy after cancer.

Authors:  Ludovic Zimmerlin; Tea Soon Park; Elias T Zambidis; Vera S Donnenberg; Albert D Donnenberg
Journal:  Biochimie       Date:  2013-06-05       Impact factor: 4.079

7.  Set9, NF-κB, and microRNA-21 mediate berberine-induced apoptosis of human multiple myeloma cells.

Authors:  Hai-yan Hu; Kun-peng Li; Xiu-ju Wang; Yuan Liu; Zhi-gang Lu; Rui-hong Dong; Hong-bo Guo; Mei-xia Zhang
Journal:  Acta Pharmacol Sin       Date:  2012-12-17       Impact factor: 6.150

Review 8.  Bottlenecks in the Efficient Use of Advanced Therapy Medicinal Products Based on Mesenchymal Stromal Cells.

Authors:  Natalia Escacena; Elena Quesada-Hernández; Vivian Capilla-Gonzalez; Bernat Soria; Abdelkrim Hmadcha
Journal:  Stem Cells Int       Date:  2015-07-27       Impact factor: 5.443

9.  Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease.

Authors:  Antonio Garcia-Gomez; Javier De Las Rivas; Enrique M Ocio; Elena Díaz-Rodríguez; Juan C Montero; Montserrat Martín; Juan F Blanco; Fermín M Sanchez-Guijo; Atanasio Pandiella; Jesús F San Miguel; Mercedes Garayoa
Journal:  Oncotarget       Date:  2014-09-30

Review 10.  Potential clinical applications of adult human mesenchymal stem cell (Prochymal®) therapy.

Authors:  Amit N Patel; Jorge Genovese
Journal:  Stem Cells Cloning       Date:  2011-11-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.